Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)

被引：1
|
作者：
Sajeev, G. [1 ]
Evans, R. [2 ]
Hawkins, N. [2 ,3 ]
Mahajan, A. [4 ]
Scott, D. [2 ]
Nam, J. [5 ]
Sutherland, S. [5 ]
Kokaliaris, C. [5 ,6 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Visible Analyt, Oxford, England
[3] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
[4] Bridge Med Consulting Ltd, London, England
[5] F Hoffmann La Roche Ltd, Global Access, Basel, Switzerland
[6] Roche Prod Ltd, Welwyn Garden City, Herts, England
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.385
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P08
引用
收藏
页码：S164 / S164
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of Nusinersen in the treatment of spinal muscular atrophy in adolescents and adults
    Ningning, W.
    Hu, Y.
    Yu, L.
    Zhu, W.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [42] Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen
    Xiao, Lena
    Chiang, Jackie
    Castro-Codesal, Maria
    Kolski, Hanna
    Bedi, Prabhjot
    Al Amrani, Fatema
    Gonorazky, Hernan D.
    Amin, Reshma
    PEDIATRIC PULMONOLOGY, 2023, 58 (01) : 161 - 170
  • [43] Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
    Guenther, Rene
    Wurster, Claudia Diana
    Brakemeier, Svenja
    Osmanovic, Alma
    Schreiber-Katz, Olivia
    Petri, Susanne
    Uzelac, Zeljko
    Hiebeler, Miriam
    Thiele, Simone
    Walter, Maggie C.
    Weiler, Markus
    Kessler, Tobias
    Freigang, Maren
    Lapp, Hanna Sophie
    Cordts, Isabell
    Lingor, Paul
    Deschauer, Marcus
    Hahn, Andreas
    Martakis, Kyriakos
    Steinbach, Robert
    Ilse, Benjamin
    Roediger, Annekathrin
    Bellut, Julia
    Nentwich, Julia
    Zeller, Daniel
    Muhandes, Mohamad Tareq
    Baum, Tobias
    Koch, Jan Christoph
    Schrank, Bertold
    Fischer, Sophie
    Hermann, Andreas
    Kamm, Christoph
    Naegel, Steffen
    Mensch, Alexander
    Weber, Markus
    Neuwirth, Christoph
    Lehmann, Helmar C.
    Wunderlich, Gilbert
    Stadler, Christian
    Tomforde, Maike
    George, Annette
    Gross, Martin
    Pechmann, Astrid
    Kirschner, Janbernd
    Tuerk, Matthias
    Schimmel, Mareike
    Bernert, Guenther
    Martin, Pascal
    Rauscher, Christian
    Hoerste, Gerd Meyer zu
    LANCET REGIONAL HEALTH-EUROPE, 2024, 39
  • [44] Sleep architecture and Nusinersen therapy in children with Spinal Muscular Atrophy type 1
    Verrillo, Elisabetta
    Pavone, Martino
    Bruni, Oliviero
    Ferri, Raffaele
    Testa, Maria Beatrice Chiarini
    Cherchi, Claudio
    D'Amico, Adele
    Cutrera, Renato
    SLEEP MEDICINE, 2023, 110 : 106 - 110
  • [45] SUNFISH parts 1 and 2: 3-year efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)
    Day, J.
    Deconinck, N.
    Mazzone, E.
    Nascimento, A.
    Oskoui, M.
    Saito, K.
    Vuillerot, C.
    Baranello, G.
    Boespflug-Tanguy, O.
    Goemans, N.
    Kirschner, J.
    Kostera-Pruszczyk, A.
    Servais, L.
    Braid, J.
    Gerber, M.
    Gorni, K.
    Martin, C.
    Scalco, R.
    Yeung, W.
    Mercuri, E.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S89 - S90
  • [46] Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study
    Finkel, Richard
    Mercuri, Eugenio
    Kirschner, Jan
    Chiriboga, Claudia A.
    Kuntz, Nancy
    Darras, Basil T.
    Shieh, Perry B.
    Saito, Kayoko
    De Vivo, Darryl
    Day, John W.
    Mazzone, Elena S.
    Montes, Jacqueline
    Yang, Qingqing
    Zhong, Zhenshao John
    Gheuens, Sarah
    Bennett, C. Frank
    Schneider, Eugene
    Farwell, Wildon
    NEUROLOGY, 2017, 89 (08) : E100 - E101
  • [47] Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy
    Kotulska, Katarzyna
    Chmielewski, Dariusz
    Mazurkiewicz-Beldzinska, Maria
    Tomaszek, Katarzyna
    Pierzchlewicz, Katarzyna
    Rabczenko, Daniel
    Przyslo, Lukasz
    Biedro, Agnieszka
    Czyzyk, Elzbieta
    Steinborn, Barbara
    Pietruszewski, Jerzy
    Bockowski, Leszek
    Cichosz, Dorota
    Dudzinska, Magdalena
    Gadowska, Elzbieta
    Mlynarczyk, Elzbieta
    Jasinski, Miroslaw
    Masztalerz, Anna
    Kempisty, Agnieszka
    Kostera-Pruszczyk, Anna
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2022, 39 : 103 - 109
  • [48] LONG-TERM FOLLOW-UP STUDY OF RISDIPLAM IN PARTICIPANTS WITH SPINAL MUSCULAR ATROPHY (WeSMA)
    Tanvir, Imran
    Lim, Elise
    Shapouri, Sheila
    Shah, Rushabh
    Sun, Christy
    Seth, Gaurav
    MUSCLE & NERVE, 2024, 70 (03) : 603 - 603
  • [49] Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil
    Fernandes, Brigida Dias
    Rodrigues, Fernanda D'Athayde
    Cirilo, Herica Nubia Cardoso
    Borges, Stefani Sousa
    Krug, Barbara Correa
    Probst, Livia Fernandes
    Zimmermann, Ivan
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 108 - 117
  • [50] Nusinersen Experience in Individuals with Spinal Muscular Atrophy (SMA) Type III: A Case Series
    Chiriboga, C.
    Kirschner, J.
    Swoboda, K.
    Mercuri, E.
    Darras, B.
    Foster, R.
    Bhan, I
    Farwell, W.
    ANNALS OF NEUROLOGY, 2018, 84 : S351 - S351
12345